Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/SELLAS Life Sciences Group, Inc./ 8-K

Current Report · Items 2.02, 8.01, 9.01 · 8-K

SELLAS Life Sciences Group, Inc.

SLSNASDAQEQUITYCurrent

Results of Operations and Financial Condition · Other Events

Item 2.02 Results of Operations and Financial Condition. As of June 30, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) estimates that its unaudited cash and cash equivalents position was $138.3 million. This amount is unaudited and preliminary and is subject to the completion of financial closing procedures, including management’s reviews.…

Filed Jul 27, 2026Accepted Jul 27, 2026, 4:35 PM EDTCIK 1390478Accession 0001104659-26-087110
View company →Permanent SEC source ↗
Share

Company context

Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com

Current securities

SLSNASDAQ · EQUITY · Current

Recent company filings

  1. Results of Operations and Financial ConditionAug 11, 2026
  2. 10-Q filingAug 11, 2026
  3. SCHEDULE 13G filingJul 31, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJun 25, 2026
  5. Submission of Matters to a Vote of Security HoldersJun 18, 2026

Disclosure sections

Items 2.02, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. As of June 30, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) estimates that its unaudited cash and cash equivalents position was $138.3 million. This amount is unaudited and preliminary and is subject to the completion of financial closing procedures, including management’s reviews. As a result, this amount may differ materially from the amount that will be reflected in the Company’s financial statements as of and for the six months ended June 30, 2026.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events As previously disclosed, the Company commenced a binding arbitration against 3D Medicines, Inc. (“3D Medicines”), administered by the Hong Kong International Arbitration Centre (“HKIAC”). On July 24, 2026, the sole arbitrator in the arbitration proceeding rendered a decision dismissing the Company’s claims. As permitted by HKIAC rules, the arbitrator administratively allocated a portion of 3D Medicines’ legal fees and costs in the amount of approximately $1.0 million to be paid by the Company. 3D Medicines announced that it will continue to progress the development and commercialization of galinpepimut-S (“GPS”) in the Greater China territory in accordance with the terms of the exclusive license agreement, pursuant to which $191.5 million in potential future milestone payments remain as of March 31, 2026, including the $13.0 million milestone payments that were in dispute in the arbitration.